婴儿髓母细胞瘤治疗差距的弥合:一种全球可行方案的分子分层结局
该回顾性研究纳入阿根廷Garrahan医院29例接受避免颅脊放疗策略(诱导化疗、局灶放疗和维持化疗)的婴儿髓母细胞瘤患儿,用DNA甲基化芯片进行分子分型并分析生存。全队列无进展生存为0.704(95%CI: 0.551-0.899);SHHγ亚型5年PFS达100%(95%CI: 0.633-1),SHHβ为0.56(95%CI: 0.42-1),Group 3为0.50(95%CI: 0.25-1)。11例评估神经认知,中位IQ为73.5。
要点
- 避免颅脊放疗的诱导化疗+局灶放疗+维持化疗方案在全球范围内可行且有效
- 分子亚型与预后显著相关,SHHγ亚型5年PFS达100%
- 多数存活患儿神经认知结局处于低平均水平至轻度智力障碍
核心结论
- 避免颅脊放疗的诱导化疗、局灶放疗和维持化疗方案在婴儿髓母细胞瘤中全球可行且有效
- 分子分型与生存显著相关,SHHγ亚型预后极佳而SHHβ和Group 3预后较差
研究设计与样本
- 回顾性分析,纳入阿根廷布宜诺斯艾利斯Garrahan医院29例接受避免颅脊放疗策略的婴儿髓母细胞瘤患儿
- 使用Illumina HumanMethylationEPIC芯片进行分子分型并与生存进行相关性分析
主要发现
- 29例患儿年龄范围0.3-4.6岁,包括17例SHH型、10例Group 3/4型和2例非髓母细胞瘤
- 全队列无进展生存(PFS)为0.704(95%CI: 0.551-0.899)
- t-SNE分析揭示3个主要分组:SHHβ、SHHγ和Group 3
- SHHγ亚型5年PFS为100%(95%CI: 0.633-1),SHHβ为0.56(95%CI: 0.42-1),Group 3为0.50(95%CI: 0.25-1)
- 11例患者进行神经认知评估,多数存活者处于低平均水平至轻度智力障碍,中位IQ为73.5
关键数值与推荐
- 全队列PFS 0.704(95%CI: 0.551-0.899)
- SHHγ亚型5年PFS 100%(95%CI: 0.633-1)
- SHHβ亚型PFS 0.56(95%CI: 0.42-1)
- Group 3亚型PFS 0.50(95%CI: 0.25-1)
- 神经认知评估中位IQ 73.5
临床怎么用
- 对于婴儿髓母细胞瘤,可考虑采用避免颅脊放疗的诱导化疗、局灶放疗和维持化疗方案
- 分子分型(SHHβ、SHHγ、Group 3)有助于预后分层和临床决策
- 治疗选择需权衡生存获益与神经认知后遗症风险
局限性
- 回顾性分析,样本量较小(29例)
- 神经认知评估仅覆盖11例患者
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infant medulloblastoma represents an enormous challenge in neuro-oncology, due to their simultaneous high-risk of recurrence and high risk of severe neurodevelopmental sequelae with craniospinal irradiation. Currently infant medulloblastoma are treated with intensified protocols, either comprising intraventricular methotrexate or autologous transplant, both of which carry significant morbidity and are not feasible in the majority of the world. We sought to evaluate the molecular predictors of outcome in a cohort of infants homogeneously treated with induction chemotherapy, focal radiation and maintenance chemotherapy. METHODS: In a retrospective analysis, 29 young children treated with a craniospinal irradiation sparing strategy from Hospital Garrahan in Buenos Aires were profiled using Illumina HumanMethylationEPIC arrays, and correlated with survival. RESULTS: Twenty-nine children (range, 0.3-4.6 y) were identified, comprising 17 sonic hedgehog (SHH), 10 Group 3/4, and 2 non-medulloblastomas. Progression-free survival (PFS) across the entire cohort was 0.704 (95% CI: 0.551-0.899). Analysis by t-distributed stochastic neighbor embedding revealed 3 predominant groups, SHHβ, SHHγ, and Group 3. Survival by subtype was highly prognostic with SHHγ having an excellent 5-year PFS of 100% (95% CI: 0.633-1) and SHHβ having a PFS of 0.56 (95% CI: 0.42-1). Group 3 had a PFS of 0.50 (95% CI: 0.25-1). Assessment of neurocognitive outcome was performed in 11 patients; the majority of survivors fell within the low average to mild intellectual disability, with a median IQ of 73.5. CONCLUSIONS: We report a globally feasible and effective strategy avoiding craniospinal radiation in the treatment of infant medulloblastoma, including a robust molecular correlation along with neurocognitive outcomes.
引用
- Baroni LV, Sampor C, Gonzalez A, et al. Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Neuro Oncol. 2020. PMID: 32413139. doi:10.1093/neuonc/noaa122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。